Novartis buys Singapore company developing IgA nephropathy drug
Click Here to Manage Email Alerts
Key takeaways:
- Novartis is acquiring SanReno Therapeutics, a company based in Singapore that is developing a treatment for IgA nephropathy.
- The sale includes exclusive rights to market the drug in China and Singapore.
Novartis has agreed to buy SanReno Therapeutics, a clinical-stage company that specializes in the development of treatments for kidney diseases, according to a press release.
Established in late 2021 as a joint venture between investors and Chinook Therapeutics, now part of Novartis, SanReno Therapeutics holds exclusive rights in China and Singapore for atrasentan and zigakibart, two therapies that target immunoglobulin A nephropathy, according to the release.
Atrasentan is an oral endothelin A receptor antagonist in phase 3 trials. Zigakibart (BION-1301) is a subcutaneously administered monoclonal antibody targeting a proliferation-inducing ligand and is in phase 3 trials, according to the release.
“The acquisition of SanReno by Novartis is a testament to the unwavering dedication and relentless innovation of the SanReno team. It validates our commitment to pushing the boundaries in kidney disease therapeutics,” Haoyu Huang, CEO of SanReno Therapeutics, said in the release. Huang added, “Today marks an exciting new chapter in our journey to making a meaningful impact in the field of renal health.”
Read more about
Click Here to Manage Email Alerts